Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dose Selection(Step 1), Non-inferiority(Step 2), Phase II/III Clinical Trials to Evaluate the Efficacy and Safety of Hepatitis B Virus-associated Liver Transplant Patients by Intravenously Injecting GC1102

Trial Profile

Dose Selection(Step 1), Non-inferiority(Step 2), Phase II/III Clinical Trials to Evaluate the Efficacy and Safety of Hepatitis B Virus-associated Liver Transplant Patients by Intravenously Injecting GC1102

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 16 May 2018

At a glance

  • Drugs GC 1102 (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors GC Pharma
  • Most Recent Events

    • 25 Apr 2018 Status changed from planning to recruiting.
    • 19 Jan 2018 New trial record
    • 17 Jan 2018 According to a Green Cross Pharma media release, the company expects to initiate patient enrollment in early 2018 and expects to complete the trial in 5 years.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top